Table 2.
Common adverse effects of cabazitaxel.
| Adverse event | All events | Grade ≥3 | Special considerations |
|---|---|---|---|
| Hematologic | |||
| Neutropenia | 347 (94%) | 303 (82%) | More common age ≥65; consider G-CSF prophylaxis |
| Leukopenia | 355 (96%) | 253 (68%) | |
| Anemia | 361 (97%) | 39 (11%) | |
| Thrombocytopenia | 176 (47%) | 15 (4%) | |
| Nonhematologic | |||
| Diarrhea | 173 (47%) | 23 (6%) | More common age ≥75 and prior radiotherapy |
| Fatigue | 136 (37%) | 18 (5%) | |
| Back pain | 60 (16%) | 14 (4%) | |
| Nausea | 127 (34%) | 7 (2%) | |
| Vomiting | 84 (23%) | 7 (2%) | |
| Hematuria | 62 (17%) | 7 (2%) | |
| Abdominal pain | 43 (12%) | 7 (2%) | |
| Dyspnea | 44 (12%) | 5 (1%) | |
| Constipation | 76 (20%) | 4 (1%) | |
| Pyrexia | 45 (12%) | 4 (1%) | |
| Arthralgia | 39 (11%) | 4 (1%) | |
| Postmarket reporting (frequency not determined) | |||
| Colitis, enterocolitis, gastritis, neutropenic enterocolitis, gastrointestinal hemorrhage and perforation, ileus and intestinal obstruction | |||
G-CSF, granulocyte colony stimulating factor.